Company
iTeos Therapeutics, Inc.
Headquarters: Cambridge, MA, United States
Employees: 74
CEO: Dr. Michel Detheux Ph.D.
Market Cap
$389.6 Million
USD as of July 1, 2025
iTeos Therapeutics, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $12.6 M |
| EBITDA | $-146,676,000 |
| Gross Profit TTM | $0 |
| Profit Margin | 0.00% |
| Operating Margin | -1171.69% |
| Quarterly Revenue Growth | -100.00% |
Stocks & Indices
iTeos Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: ITOS wb_incandescent